ADCT — ADC Therapeutics SA Share Price
Last trade - 00:00- $131.91m
- $314.77m
- $70.84m
- 20
- 31
- 28
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.86 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -54.1% | ||
| Return on Equity | n/a | ||
| Operating Margin | -184.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 33.92 | 209.91 | 69.56 | 70.84 | 74.18 | 87.95 | 97.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Directors
- Ron Squarer NEC (54)
- Christopher Martin CEO (62)
- Michael Forer VCH (55)
- Jennifer Creel CFO (50)
- Kimberly Pope CHO (54)
- Joseph Camardo SVP
- Jennifer Herron SVP (51)
- Patrick Van Berkel SVP (52)
- Robert Schmidt CAO (43)
- Susan Romanus CCO (55)
- Lisa Skelton VPR (53)
- Richard Onyett VBD (73)
- Peter Greaney OTH (41)
- Viviane Monges DRC (58)
- Thomas Pfisterer NED (39)
- Tyrell Rivers NED (48)
- Victor Sandor NED (54)
- Peter Corr NID (72)
- Stephen Evans-freke NID (68)
- Peter Hug NID (62)
- Thomas Rinderknecht NID (67)
- Jacques Theurillat NID (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 6th, 2011
- Public Since
- May 15th, 2020
- No. of Shareholders
- 170
- No. of Employees
- 263
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 99,178,286
- Address
- Biopole, route de la Corniche 3B, EPALINGES, 1066
- Web
- https://adctherapeutics.com/
- Phone
- +41 216530200
- Contact
- Nicole Riley
- Auditors
- PricewaterhouseCoopers SA
Latest News for ADCT
Upcoming Events for ADCT
Q1 2025 ADC Therapeutics SA Earnings Release
ADC Therapeutics SA Annual Shareholders Meeting
ADC Therapeutics SA Annual Shareholders Meeting
Q2 2025 ADC Therapeutics SA Earnings Release
Similar to ADCT
Alto Neuroscience
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Aurion Biotech
New York Stock Exchange
Biohaven
New York Stock Exchange
FAQ
As of Today at 19:04 UTC, shares in ADC Therapeutics SA are trading at $1.33. This share price information is delayed by 15 minutes.
Shares in ADC Therapeutics SA last closed at $1.33 and the price had moved by -70.05% over the past 365 days. In terms of relative price strength the ADC Therapeutics SA share price has underperformed the S&P500 Index by -72.35% over the past year.
The overall consensus recommendation for ADC Therapeutics SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreADC Therapeutics SA does not currently pay a dividend.
ADC Therapeutics SA does not currently pay a dividend.
ADC Therapeutics SA does not currently pay a dividend.
To buy shares in ADC Therapeutics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.33, shares in ADC Therapeutics SA had a market capitalisation of $131.91m.
Here are the trading details for ADC Therapeutics SA:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ADCT
Based on an overall assessment of its quality, value and momentum ADC Therapeutics SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ADC Therapeutics SA is $8.20. That is 516.54% above the last closing price of $1.33.
Analysts covering ADC Therapeutics SA currently have a consensus Earnings Per Share (EPS) forecast of -$1.62 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ADC Therapeutics SA. Over the past six months, its share price has underperformed the S&P500 Index by -52.48%.
As of the last closing price of $1.33, shares in ADC Therapeutics SA were trading -43.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ADC Therapeutics SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ADC Therapeutics SA's management team is headed by:
- Ron Squarer - NEC
- Christopher Martin - CEO
- Michael Forer - VCH
- Jennifer Creel - CFO
- Kimberly Pope - CHO
- Joseph Camardo - SVP
- Jennifer Herron - SVP
- Patrick Van Berkel - SVP
- Robert Schmidt - CAO
- Susan Romanus - CCO
- Lisa Skelton - VPR
- Richard Onyett - VBD
- Peter Greaney - OTH
- Viviane Monges - DRC
- Thomas Pfisterer - NED
- Tyrell Rivers - NED
- Victor Sandor - NED
- Peter Corr - NID
- Stephen Evans-freke - NID
- Peter Hug - NID
- Thomas Rinderknecht - NID
- Jacques Theurillat - NID